Orchestra BioMed Holdings, Inc.(OBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,441 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
OBIO Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Orchestra BioMed Holdings, Inc. (OBIO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OBIO at 32.0/100 on a 32-signal composite quality model, placing it at rank #2,441 of 2,961 stocks — the bottom half of the AI-ranked universe. OBIO scores in the top quartile across revenue growth (99.3), institutional flow (82.5). Areas of concern include balance sheet strength (1.9) and free cash flow (4.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Orchestra BioMed Holdings, Inc. reports quarterly revenue of $88.0K, net income of $-23.8M, free cash flow of $-19.6M. Top institutional holders of OBIO by reported 13-F value include RTW INVESTMENTS, PERCEPTIVE ADVISORS, BlackRock, based on the most recent SEC filings. OBIO trades on the Nasdaq exchange and files with the SEC under CIK 1814114. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Orchestra BioMed Holdings, Inc. directly from SEC EDGAR. Orchestra BioMed Holdings, Inc.'s 13F Pro composite quality score has ranged between 10 and 32 since 2026, currently 32.0 — an improving long-term trajectory across 34 quarterly and live scoring snapshots.
Revenue
Q2 2026
$88.0K
Net Income
Q2 2026
$-23.8M
Free Cash Flow
Q2 2026
$-19.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+1169.2% YoYNet Income
+13.6% YoYOperating Income
+19.4% YoYEPS (Diluted)
+33.1% YoYTotal Assets
+50.8% YoYTotal Debt
+0.0% YoYOp. Cash Flow
+3.2% YoYFree Cash Flow
+2.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $33.5M +1169.2% | $2.6M -4.4% | $2.8M -21.9% | $3.5M | — | — |
| Net Income | $-52.7M +13.6% | $-61.0M -24.2% | $-49.1M -46.2% | $-33.6M -8773.3% | $-378.8K | — |
| Operating Income | $-51.8M +19.4% | $-64.3M -24.8% | $-51.5M -57.7% | $-32.7M -8172.7% | $-394.8K | — |
| EPS (Diluted) | $-1.11 +33.1% | $-1.66 -12.2% | $-1.48 +33.9% | $-2.24 -11100.0% | $-0.02 | — |
| Total Assets | $114.9M +50.8% | $76.2M -20.0% | $95.2M -0.4% | $95.6M -40.9% | $161.8M -0.2% | $162.2M |
| Total Debt | $15.0M +0.0% | $15.0M | — | — | — | — |
| Operating Cash Flow | $-49.0M +3.2% | $-50.6M -9.6% | $-46.1M -57.5% | $-29.3M -10653.7% | $-272.4K | — |
| Free Cash Flow | $-49.5M +2.7% | $-50.8M -10.0% | $-46.2M -54.6% | $-29.9M | — | — |
Get alerted when OBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Orchestra BioMed Holdings, Inc. including:
Top Institutional Holders of OBIO
RTW INVESTMENTS, LP
$41.2M9,556,063 shPERCEPTIVE ADVISORS LLC
$21.7M5,037,906 shBlackRock, Inc.
$10.8M2,510,387 shVANGUARD CAPITAL MANAGEMENT LLC
$8.7M2,022,916 shGEODE CAPITAL MANAGEMENT, LLC
$4.4M1,007,908 shAlyeska Investment Group, L.P.
$4.3M1,000,000 shPropel Bio Management, LLC
$3.9M896,701 shUBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME
$2.8M642,154 shSTATE STREET CORP
$2.2M516,050 shRICE HALL JAMES & ASSOCIATES, LLC
$1.8M424,000 sh
| Fund | Value | Shares |
|---|---|---|
| RTW INVESTMENTS, LP | $41.2M | 9,556,063 |
| PERCEPTIVE ADVISORS LLC | $21.7M | 5,037,906 |
| BlackRock, Inc. | $10.8M | 2,510,387 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.7M | 2,022,916 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.4M | 1,007,908 |
| Alyeska Investment Group, L.P. | $4.3M | 1,000,000 |
| Propel Bio Management, LLC | $3.9M | 896,701 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME | $2.8M | 642,154 |
| STATE STREET CORP | $2.2M | 516,050 |
| RICE HALL JAMES & ASSOCIATES, LLC | $1.8M | 424,000 |
Companies Similar to OBIO
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
LENZ Therapeutics, Inc.
Upstream Bio, Inc.
4D Molecular Therapeutics, Inc.
Phathom Pharmaceuticals, Inc.
Invivyd, Inc.
Kura Oncology, Inc.
Century Therapeutics, Inc.
LEXICON PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put OBIO on your watchlist
Track score changes the day Orchestra BioMed Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OBIO a good stock to buy?
13F Pro's AI-powered analysis of Orchestra BioMed Holdings, Inc. (OBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OBIO are available on the OBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OBIO is classified as a small company.
Which hedge funds own OBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Orchestra BioMed Holdings, Inc.'s investment landscape.